A phase II study of combination chemotherapy with docetaxel and carboplatin for elderly patients with advanced non-small cell lung cancer

Lung Cancer

Volumn 68, Issue 2, 2010, Pages 248-252

  Kim, Hye Jin ^a   Kim, Tae Gyoon ^a   Lee, Hyun Jeong ^a   Kim, Jee Ho ^a   Lim, Byung Hoon ^a   Seo, Jae Won ^a   Kang, Eun Mi ^a   Lee, Byung Uk ^a   Ahn, Young Mi ^a   Roh, Yong Ho ^a   Nam, Seung Hyun ^a   Kim, Bong Seog ^a  

^a Seoul Veterans Hospital   (South Korea)

Author keywords

Carboplatin; Chemotherapy; Docetaxel; Elderly; Lung cancer

Indexed keywords

CARBOPLATIN; DOCETAXEL;

AGED; ALOPECIA; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; COMORBIDITY; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELDERLY CARE; FEMALE; FOLLOW UP; HUMAN; LIVER METASTASIS; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; SCORING SYSTEM; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASM STAGING; SURVIVAL ANALYSIS; TAXOIDS;

EID: 77950460993     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2009.06.026     Document Type: Article

References (36)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., Thun M.J. Cancer statistics, 2007. CA Cancer J Clin 2007, 57:43-66.
2. Gridelli C., Aapro M., Ardizzoni A., Balducci L., De Marinis F., Kelly K., et al. Treatment of advanced non-small-cell lung cancer in the elderly: results of an international expert panel. J Clin Oncol 2005, 23:3125-3137.
3. Gridelli C. Does chemotherapy have a role as palliative therapy for unfit or elderly patients with non-small-cell lung cancer?. Lung Cancer 2002, 38:S45-S50.
4. Spiro S.G., Silvestri G.A. The treatment of advanced non-small cell lung cancer. Curr Opin Pulm Med 2005, 11:287-291.
5. Gridelli C., Perrone F., Monfardini S. Lung cancer in the elderly. Eur J Cancer 1997, 33:2313-2314.
6. Fentiman I.S., Tirelli U., Monfardini S., Schneider M., Festen J., Cognetti F., et al. Cancer in the elderly: why so badly treated?. Lancet 1990, 335:1020-1022.
7. Albain K.S., Crowley J.J., LeBlanc M., Livingston R.B. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 1991, 9:1618-1626.
8. Finkelstein D.M., Ettinger D.S., Ruckdeschel J.C. Long-term survivors in metastatic non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study. J Clin Oncol 1986, 4:702-709.
9. Stanley K.E. Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst 1980, 65:25-32.
10. Gridelli C., Perrone F., Gallo C., De Marinis F., Ianniello G., Cigolari S., et al. Vinorelbine is well tolerated and active in the treatment of elderly patients with advanced non-small cell lung cancer. A two-stage phase II study. Eur J Cancer 1997, 33:392-397.
11. Gridelli C., Manegold C., Mali P., Reck M., Portalone L., Castelnau O., et al. Oral vinorelbine given as monotherapy to advanced, elderly NSCLC patients: a multicentre phase II trial. Eur J Cancer 2004, 40:2424-2431.
12. Altavilla G., Adamo V., Buemi B., Marabello G., Maisano R., Lupo G., et al. Gemcitabine as single agent in the treatment of elderly patients with advanced non small cell lung cancer. Anticancer Res 2000, 20:3675-3678.
13. Martoni A., Di Fabio F., Guaraldi M., Piana E., Ramini R., Lelli G., et al. Prospective phase II study of single-agent gemcitabine in untreated elderly patients with stage IIIB/IV non-small-cell lung cancer. Am J Clin Oncol 2001, 24:614-617.
14. Fidias P., Supko J.G., Martins R., Boral A., Carey R., Grossbard M., et al. A phase II study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer. Clin Cancer Res 2001, 7:3942-3949.
15. Gridelli C. The ELVIS trial: a phase III study of single-agent vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer. Elderly Lung Cancer Vinorelbine Italian Study. Oncologist 2001, 6:4-7.
16. Frasci G., Lorusso V., Panza N., Comella P., Nicolella G., Bianco A., et al. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol 2000, 18:2529-2536.
17. Gridelli C., Perrone F., Gallo C., Cigolari S., Rossi A., Piantedosi F., et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 2003, 95:362-372.
18. Pfister D.G., Johnson D.H., Azzoli C.G., Sause W., Smith T.J., Baker S., et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004, 22:330-353.
19. Felip E.S.R., Pavlidis N. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of non-small-cell lung cancer (NSCLC). Ann Oncol 2005, 16:28-29.
20. Langer C.J., Manola J., Bernardo P., Kugler J.W., Bonomi P., Cella D., et al. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 2002, 94:173-181.
21. Belani C.P., Fossella F. Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326). Cancer 2005, 104:2766-2774.
22. Choi I.S., Kim B.S., Park S.R., Lee S.Y., Kim D.Y., Kim J.H., et al. Efficacy of modified regimen with attenuated doses of paclitaxel plus carboplatin combination chemotherapy in elderly and/or weak patients with advanced non-small cell lung cancer. Lung Cancer 2003, 39:99-101.
23. Okamoto I., Moriyama E., Fujii S., Kishi H., Nomura M., Goto E., et al. Phase II study of carboplatin-paclitaxel combination chemotherapy in elderly patients with advanced non-small cell lung cancer. Jpn J Clin Oncol 2005, 35:188-194.
24. Giorgio C.G., Pappalardo A., Russo A., Giuffrida D., Santini D., Petralia G., et al. A phase II study of carboplatin and paclitaxel as first line chemotherapy in elderly patients with advanced non-small cell lung cancer (NSCLC). Lung Cancer 2006, 51:357-362.
25. Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40:373-383.
26. Cockcroft D.W., Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 1976, 16:31-41.
27. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
28. Trotti A., Colevas A.D., Setser A., Rusch V., Jaques D., Budach V., et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003, 13:176-181.
29. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989, 10:1-10.
30. Belani C.P., Einzig A., Bonomi P., Dobbs T., Capozzoli M.J., Earhart R., et al. Multicenter phase II trial of docetaxel and carboplatin in patients with stage IIIB and IV non-small-cell lung cancer. Ann Oncol 2000, 11:673-678.
31. Zarogoulidis K., Kontakiotis T., Hatziapostolou P., Fachantidou E., Delis D., Goutsikas J., et al. A Phase II study of docetaxel and carboplatin in the treatment of non-small cell lung cancer. Lung Cancer 2001, 32:281-287.
32. Millward M.J., Boyer M.J., Lehnert M., Clarke S., Rischin D., Goh B.C., et al. Docetaxel and carboplatin is an active regimen in advanced non-small-cell lung cancer: a phase II study in Caucasian and Asian patients. Ann Oncol 2003, 14:449-454.
33. Kudoh S., Takeda K., Nakagawa K., Takada M., Katakami N., Matsui K., et al. Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J Clin Oncol 2006, 24:3657-3663.
34. Hainsworth J.D., Burris H.A., Litchy S., Morrissey L.H., Barton J.H., Bradof J.E., et al. Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma. A Minnie Pearl Cancer Research Network Phase II Trial. Cancer 2000, 89:328-333.
35. Lilenbaum R., Rubin M., Samuel J., Boros L., Chidiac T., Seigel L., et al. A randomized phase II trial of two schedules of docetaxel in elderly or poor performance status patients with advanced non-small cell lung cancer. J Thorac Oncol 2007, 2:306-311.
36. Yoshimura N., Kudoh S., Kimura T., Mitsuoka S., Kyoh S., Tochino Y., et al. Phase II study of docetaxel and carboplatin in elderly patients with advanced non-small cell lung cancer. J Thorac Oncol 2009, 4:371-375.